Ixovex-1 Single Agent and Combination Therapy

This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection. This will be assessed in patients with palpable locally advanced, unresectable, or metastatic tumours, for whom all approved therapeutic options have been exhausted, are not available, are unlikely to have significant clinical benefit, or are declined by the patient.

Trial Details

NCT ID
NCT06549946
Phase
PHASE1 / PHASE2
Sponsor
Psivac Ltd
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Ixovex-1
  • Pembrolizumab
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (IC…
  • Female or male subjects aged ≥18 years (local regulatory requirements should be followed if the legal age of consent for study participation is \>1…
  • Subjects with injectable locally advanced, unresectable, or metastatic solid tumours.
  • In Phase Ia and Phase Ib, all solid tumour types will be accepted.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →